Teva sells off global women’s health portfolio in $1.38bn deal

Serialisation in pharmaceutical production
Credit: Julia Sudnitskaya

Teva Pharmaceutical Industries is selling the remaining assets of its specialty global women’s health business for $1.38 billion.

It will use the proceeds from the sales – combined with those of the recent Paragard sale – to progress repayment of term loan debt.

The remaining assets have been sold off in two separate agreements.

The first is to CVC Capital Partners Fund VI who will acquire a portfolio of products across contraception, fertility, menopause and osteoporosis for $703 million.

The second agreement involves Foundation Consumer Healthcare acquiring Plan B One-Step and Teva’s value brands of emergency contraception, Take Action, Aftera, and Next Choice One Dose for $675 million.

Teva is also planning the divestiture of the Oncology and Pain business in Europe.